APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Manufacturing Execution Systems for Pharma and Biotech

Compare research editions
View pricing & licenses

Selected research

Industry Research

Manufacturing Execution Systems for Pharma and Biotech Industry Research Report 2026

Report ID 17418203051 January 2026125 pages

Choose your research edition.

Industry ResearchManufacturing Execution Systems for Pharma and Biotech Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Manufacturing Execution Systems for Pharma and Biotech Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Manufacturing Execution Systems for Pharma and Biotech Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Manufacturing Execution Systems for Pharma and Biotech Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Manufacturing Execution Systems for Pharma and Biotech Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Manufacturing Execution Systems for Pharma and Biotech market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Manufacturing Execution Systems for Pharma and Biotech market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Manufacturing Execution Systems for Pharma and Biotech market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Manufacturing Execution Systems for Pharma and Biotech market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Manufacturing Execution Systems for Pharma and Biotech include Lonza, Vimachem, Korber, MasterControl, POMS Corporation, AspenTech, GE Vernova, 凯睿德 and Dassault Systemes, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Manufacturing Execution Systems for Pharma and Biotech market in terms of revenue (US$ million) and, where applicable, service volume (Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Manufacturing Execution Systems for Pharma and Biotech.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Manufacturing Execution Systems for Pharma and Biotech Market by Company

Lonza

Vimachem

Korber

MasterControl

POMS Corporation

AspenTech

GE Vernova

凯睿德

Dassault Systemes

IBM

Rockwell Automation

ABB

Accevo Systems

AmpleLogic

Siemens Software

NNIT

Metronik

Tulip

Manufacturing Execution Systems for Pharma and Biotech Segment by Type

Cloud-based

On-premises

Manufacturing Execution Systems for Pharma and Biotech Segment by Application

Large Enterprises

SMEs

Manufacturing Execution Systems for Pharma and Biotech Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Manufacturing Execution Systems for Pharma and Biotech market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Manufacturing Execution Systems for Pharma and Biotech and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Manufacturing Execution Systems for Pharma and Biotech.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Manufacturing Execution Systems for Pharma and Biotech companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Manufacturing Execution Systems for Pharma and Biotech Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Type (2021-2026) Table 7. Global Manufacturing Execution Systems for Pharma and Biotech Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Type (2027-2032) Table 9. Global Manufacturing Execution Systems for Pharma and Biotech Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Application (2021-2026) Table 11. Global Manufacturing Execution Systems for Pharma and Biotech Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Application (2027-2032) Table 13. Global Manufacturing Execution Systems for Pharma and Biotech Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Manufacturing Execution Systems for Pharma and Biotech Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Manufacturing Execution Systems for Pharma and Biotech Market Share by Region (2021-2026) Table 16. Global Manufacturing Execution Systems for Pharma and Biotech Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Manufacturing Execution Systems for Pharma and Biotech Market Share by Region (2027-2032) Table 18. Manufacturing Execution Systems for Pharma and Biotech Industry Trends Table 19. Manufacturing Execution Systems for Pharma and Biotech Industry Drivers Table 20. Manufacturing Execution Systems for Pharma and Biotech Industry Opportunities and Challenges Table 21. Manufacturing Execution Systems for Pharma and Biotech Market Restraints Table 22. Global Top Manufacturing Execution Systems for Pharma and Biotech Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Players (2021-2026) Table 24. Global Manufacturing Execution Systems for Pharma and Biotech Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Manufacturing Execution Systems for Pharma and Biotech, Headquarters and Area Served Table 26. Global Manufacturing Execution Systems for Pharma and Biotech Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Manufacturing Execution Systems for Pharma and Biotech by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Manufacturing Execution Systems for Pharma and Biotech Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Manufacturing Execution Systems for Pharma and Biotech Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Manufacturing Execution Systems for Pharma and Biotech Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Manufacturing Execution Systems for Pharma and Biotech Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Manufacturing Execution Systems for Pharma and Biotech Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Manufacturing Execution Systems for Pharma and Biotech Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2027-2032) & (US$ Million) Table 45. Lonza Company Information Table 46. Lonza Business Overview Table 47. Lonza Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 48. Lonza Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 49. Lonza Recent Developments Table 50. Vimachem Company Information Table 51. Vimachem Business Overview Table 52. Vimachem Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 53. Vimachem Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 54. Vimachem Recent Developments Table 55. Korber Company Information Table 56. Korber Business Overview Table 57. Korber Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 58. Korber Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 59. Korber Recent Developments Table 60. MasterControl Company Information Table 61. MasterControl Business Overview Table 62. MasterControl Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 63. MasterControl Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 64. MasterControl Recent Developments Table 65. POMS Corporation Company Information Table 66. POMS Corporation Business Overview Table 67. POMS Corporation Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 68. POMS Corporation Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 69. POMS Corporation Recent Developments Table 70. AspenTech Company Information Table 71. AspenTech Business Overview Table 72. AspenTech Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 73. AspenTech Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 74. AspenTech Recent Developments Table 75. GE Vernova Company Information Table 76. GE Vernova Business Overview Table 77. GE Vernova Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 78. GE Vernova Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 79. GE Vernova Recent Developments Table 80. 凯睿德 Company Information Table 81. 凯睿德 Business Overview Table 82. 凯睿德 Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 83. 凯睿德 Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 84. 凯睿德 Recent Developments Table 85. Dassault Systemes Company Information Table 86. Dassault Systemes Business Overview Table 87. Dassault Systemes Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 88. Dassault Systemes Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 89. Dassault Systemes Recent Developments Table 90. IBM Company Information Table 91. IBM Business Overview Table 92. IBM Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 93. IBM Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 94. IBM Recent Developments Table 95. Rockwell Automation Company Information Table 96. Rockwell Automation Business Overview Table 97. Rockwell Automation Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 98. Rockwell Automation Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 99. Rockwell Automation Recent Developments Table 100. ABB Company Information Table 101. ABB Business Overview Table 102. ABB Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 103. ABB Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 104. ABB Recent Developments Table 105. Accevo Systems Company Information Table 106. Accevo Systems Business Overview Table 107. Accevo Systems Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 108. Accevo Systems Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 109. Accevo Systems Recent Developments Table 110. AmpleLogic Company Information Table 111. AmpleLogic Business Overview Table 112. AmpleLogic Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 113. AmpleLogic Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 114. AmpleLogic Recent Developments Table 115. Siemens Software Company Information Table 116. Siemens Software Business Overview Table 117. Siemens Software Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 118. Siemens Software Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 119. Siemens Software Recent Developments Table 120. NNIT Company Information Table 121. NNIT Business Overview Table 122. NNIT Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 123. NNIT Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 124. NNIT Recent Developments Table 125. Metronik Company Information Table 126. Metronik Business Overview Table 127. Metronik Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 128. Metronik Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 129. Metronik Recent Developments Table 130. Tulip Company Information Table 131. Tulip Business Overview Table 132. Tulip Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) & (US$ Million) Table 133. Tulip Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 134. Tulip Recent Developments Table 135. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Manufacturing Execution Systems for Pharma and Biotech Product Image Figure 5. Global Manufacturing Execution Systems for Pharma and Biotech Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Manufacturing Execution Systems for Pharma and Biotech Market Share by Type: 2025 VS 2032 Figure 7. Cloud-based Product Figure 8. On-premises Product Figure 9. Global Manufacturing Execution Systems for Pharma and Biotech Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Manufacturing Execution Systems for Pharma and Biotech Market Share by Application: 2025 VS 2032 Figure 11. Large Enterprises Product Figure 12. SMEs Product Figure 13. Global Manufacturing Execution Systems for Pharma and Biotech Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 14. Global Manufacturing Execution Systems for Pharma and Biotech Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Manufacturing Execution Systems for Pharma and Biotech Market Share by Region: 2025 VS 2032 Figure 16. Global Manufacturing Execution Systems for Pharma and Biotech Market Share by Players in 2025 Figure 17. Global Manufacturing Execution Systems for Pharma and Biotech Manufacturers Established Date Figure 18. Global Top 5 and 10 Manufacturing Execution Systems for Pharma and Biotech Players Market Share by Revenue in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. North America Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 21. North America Manufacturing Execution Systems for Pharma and Biotech Market Share by Country (2021-2032) Figure 22. United States Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 23. Canada Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Mexico Manufacturing Execution Systems for Pharma and Biotech Market Share by Country (2021-2032) Figure 25. Europe Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 26. Europe Manufacturing Execution Systems for Pharma and Biotech Market Share by Country (2021-2032) Figure 27. Germany Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 28. France Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. U.K. Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. Italy Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Spain Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Russia Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Netherlands Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Nordic Countries Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Manufacturing Execution Systems for Pharma and Biotech Market Share by Country (2021-2032) Figure 37. China Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Japan Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. South Korea Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. India Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. India Manufacturing Execution Systems for Pharma and Biotech Market Share by Country (2021-2032) Figure 42. Australia Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. China Taiwan Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. Southeast Asia Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. South America Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. South America Manufacturing Execution Systems for Pharma and Biotech Market Share by Country (2021-2032) Figure 47. Brazil Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. Argentina Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. Chile Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Colombia Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Peru Manufacturing Execution Systems for Pharma and Biotech Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Lonza Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 53. Vimachem Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 54. Korber Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 55. MasterControl Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 56. POMS Corporation Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 57. AspenTech Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 58. GE Vernova Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 59. 凯睿德 Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 60. Dassault Systemes Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 61. IBM Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 62. Rockwell Automation Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 63. ABB Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 64. Accevo Systems Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 65. AmpleLogic Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 66. Siemens Software Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 67. NNIT Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 68. Metronik Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026) Figure 69. Tulip Revenue Growth Rate in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)

Scope & coverage.

Types
  • Cloud-based
  • On-premises
Applications
  • Large Enterprises
  • SMEs
Companies covered
  • Lonza
  • Vimachem
  • Korber
  • MasterControl
  • POMS Corporation
  • AspenTech
  • GE Vernova
  • 凯睿德
  • Dassault Systemes
  • IBM
  • Rockwell Automation
  • ABB
  • Accevo Systems
  • AmpleLogic
  • Siemens Software
  • NNIT
  • Metronik
  • Tulip

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Manufacturing Execution Systems for Pharma and Biotech by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Cloud-based
  5. 2.2.3 On-premises
  6. 2.3 Manufacturing Execution Systems for Pharma and Biotech by Application
  7. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  8. 2.3.2 Large Enterprises
  9. 2.3.3 SMEs
  10. 2.4 Assumptions and Limitations
3 Manufacturing Execution Systems for Pharma and Biotech Breakdown Data by Type
  1. 3.1 Global Manufacturing Execution Systems for Pharma and Biotech Historic Market Size by Type (2021-2026)
  2. 3.2 Global Manufacturing Execution Systems for Pharma and Biotech Forecasted Market Size by Type (2027-2032)
4 Manufacturing Execution Systems for Pharma and Biotech Breakdown Data by Application
  1. 4.1 Global Manufacturing Execution Systems for Pharma and Biotech Historic Market Size by Application (2021-2026)
  2. 4.2 Global Manufacturing Execution Systems for Pharma and Biotech Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Manufacturing Execution Systems for Pharma and Biotech Market Perspective (2021-2032)
  2. 5.2 Global Manufacturing Execution Systems for Pharma and Biotech Growth Trends by Region
  3. 5.2.1 Global Manufacturing Execution Systems for Pharma and Biotech Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Manufacturing Execution Systems for Pharma and Biotech Historic Market Size by Region (2021-2026)
  5. 5.2.3 Manufacturing Execution Systems for Pharma and Biotech Forecasted Market Size by Region (2027-2032)
  6. 5.3 Manufacturing Execution Systems for Pharma and Biotech Market Dynamics
  7. 5.3.1 Manufacturing Execution Systems for Pharma and Biotech Industry Trends
  8. 5.3.2 Manufacturing Execution Systems for Pharma and Biotech Market Drivers
  9. 5.3.3 Manufacturing Execution Systems for Pharma and Biotech Market Challenges
  10. 5.3.4 Manufacturing Execution Systems for Pharma and Biotech Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Manufacturing Execution Systems for Pharma and Biotech Players by Revenue
  2. 6.1.1 Global Top Manufacturing Execution Systems for Pharma and Biotech Players by Revenue (2021-2026)
  3. 6.1.2 Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Manufacturing Execution Systems for Pharma and Biotech Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Manufacturing Execution Systems for Pharma and Biotech Head Office and Area Served
  6. 6.4 Global Manufacturing Execution Systems for Pharma and Biotech Players, Product Type & Application
  7. 6.5 Global Manufacturing Execution Systems for Pharma and Biotech Manufacturers Established Date
  8. 6.6 Global Manufacturing Execution Systems for Pharma and Biotech Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Manufacturing Execution Systems for Pharma and Biotech Market Size (2021-2032)
  2. 7.2 North America Manufacturing Execution Systems for Pharma and Biotech Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2021-2026)
  4. 7.4 North America Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Manufacturing Execution Systems for Pharma and Biotech Market Size (2021-2032)
  2. 8.2 Europe Manufacturing Execution Systems for Pharma and Biotech Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2021-2026)
  4. 8.4 Europe Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Manufacturing Execution Systems for Pharma and Biotech Market Size (2021-2032)
  2. 9.2 Asia-Pacific Manufacturing Execution Systems for Pharma and Biotech Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Manufacturing Execution Systems for Pharma and Biotech Market Size (2021-2032)
  2. 10.2 South America Manufacturing Execution Systems for Pharma and Biotech Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2021-2026)
  4. 10.4 South America Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Manufacturing Execution Systems for Pharma and Biotech Market Size (2021-2032)
  2. 11.2 Middle East & Africa Manufacturing Execution Systems for Pharma and Biotech Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Manufacturing Execution Systems for Pharma and Biotech Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Lonza
  2. 12.1.1 Lonza Company Information
  3. 12.1.2 Lonza Business Overview
  4. 12.1.3 Lonza Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  5. 12.1.4 Lonza Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  6. 12.1.5 Lonza Recent Developments
  7. 12.2 Vimachem
  8. 12.2.1 Vimachem Company Information
  9. 12.2.2 Vimachem Business Overview
  10. 12.2.3 Vimachem Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  11. 12.2.4 Vimachem Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  12. 12.2.5 Vimachem Recent Developments
  13. 12.3 Korber
  14. 12.3.1 Korber Company Information
  15. 12.3.2 Korber Business Overview
  16. 12.3.3 Korber Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  17. 12.3.4 Korber Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  18. 12.3.5 Korber Recent Developments
  19. 12.4 MasterControl
  20. 12.4.1 MasterControl Company Information
  21. 12.4.2 MasterControl Business Overview
  22. 12.4.3 MasterControl Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  23. 12.4.4 MasterControl Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  24. 12.4.5 MasterControl Recent Developments
  25. 12.5 POMS Corporation
  26. 12.5.1 POMS Corporation Company Information
  27. 12.5.2 POMS Corporation Business Overview
  28. 12.5.3 POMS Corporation Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  29. 12.5.4 POMS Corporation Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  30. 12.5.5 POMS Corporation Recent Developments
  31. 12.6 AspenTech
  32. 12.6.1 AspenTech Company Information
  33. 12.6.2 AspenTech Business Overview
  34. 12.6.3 AspenTech Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  35. 12.6.4 AspenTech Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  36. 12.6.5 AspenTech Recent Developments
  37. 12.7 GE Vernova
  38. 12.7.1 GE Vernova Company Information
  39. 12.7.2 GE Vernova Business Overview
  40. 12.7.3 GE Vernova Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  41. 12.7.4 GE Vernova Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  42. 12.7.5 GE Vernova Recent Developments
  43. 12.8 凯睿德
  44. 12.8.1 凯睿德 Company Information
  45. 12.8.2 凯睿德 Business Overview
  46. 12.8.3 凯睿德 Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  47. 12.8.4 凯睿德 Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  48. 12.8.5 凯睿德 Recent Developments
  49. 12.9 Dassault Systemes
  50. 12.9.1 Dassault Systemes Company Information
  51. 12.9.2 Dassault Systemes Business Overview
  52. 12.9.3 Dassault Systemes Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  53. 12.9.4 Dassault Systemes Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  54. 12.9.5 Dassault Systemes Recent Developments
  55. 12.10 IBM
  56. 12.10.1 IBM Company Information
  57. 12.10.2 IBM Business Overview
  58. 12.10.3 IBM Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  59. 12.10.4 IBM Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  60. 12.10.5 IBM Recent Developments
  61. 12.11 Rockwell Automation
  62. 12.11.1 Rockwell Automation Company Information
  63. 12.11.2 Rockwell Automation Business Overview
  64. 12.11.3 Rockwell Automation Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  65. 12.11.4 Rockwell Automation Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  66. 12.11.5 Rockwell Automation Recent Developments
  67. 12.12 ABB
  68. 12.12.1 ABB Company Information
  69. 12.12.2 ABB Business Overview
  70. 12.12.3 ABB Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  71. 12.12.4 ABB Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  72. 12.12.5 ABB Recent Developments
  73. 12.13 Accevo Systems
  74. 12.13.1 Accevo Systems Company Information
  75. 12.13.2 Accevo Systems Business Overview
  76. 12.13.3 Accevo Systems Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  77. 12.13.4 Accevo Systems Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  78. 12.13.5 Accevo Systems Recent Developments
  79. 12.14 AmpleLogic
  80. 12.14.1 AmpleLogic Company Information
  81. 12.14.2 AmpleLogic Business Overview
  82. 12.14.3 AmpleLogic Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  83. 12.14.4 AmpleLogic Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  84. 12.14.5 AmpleLogic Recent Developments
  85. 12.15 Siemens Software
  86. 12.15.1 Siemens Software Company Information
  87. 12.15.2 Siemens Software Business Overview
  88. 12.15.3 Siemens Software Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  89. 12.15.4 Siemens Software Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  90. 12.15.5 Siemens Software Recent Developments
  91. 12.16 NNIT
  92. 12.16.1 NNIT Company Information
  93. 12.16.2 NNIT Business Overview
  94. 12.16.3 NNIT Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  95. 12.16.4 NNIT Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  96. 12.16.5 NNIT Recent Developments
  97. 12.17 Metronik
  98. 12.17.1 Metronik Company Information
  99. 12.17.2 Metronik Business Overview
  100. 12.17.3 Metronik Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  101. 12.17.4 Metronik Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  102. 12.17.5 Metronik Recent Developments
  103. 12.18 Tulip
  104. 12.18.1 Tulip Company Information
  105. 12.18.2 Tulip Business Overview
  106. 12.18.3 Tulip Revenue in Manufacturing Execution Systems for Pharma and Biotech Business (2021-2026)
  107. 12.18.4 Tulip Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  108. 12.18.5 Tulip Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst